Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay (scientific article published on 9 April 2013)

Identification of potent chemotypes targeting Leishmania major using a high-throughput, low-stringency, computationally enhanced, small molecule screen

Q28471705

Antileishmanial high-throughput drug screening reveals drug candidates with new scaffolds

Q28473835

Identification of small molecule lead compounds for visceral leishmaniasis using a novel ex vivo splenic explant model system

Q28477163

A screen against Leishmania intracellular amastigotes: comparison to a promastigote screen and identification of a host cell-specific hit

Q28479211

A static-cidal assay for Trypanosoma brucei to aid hit prioritisation for progression into drug discovery programmes

Q28485370

Novel compounds active against Leishmania major

Q30807168

Lessons learnt from assembling screening libraries for drug discovery for neglected diseases

Q33309109

Rapid fluorescent assay for screening drugs on Leishmania amastigotes

Q33345948

Control of the leishmaniases

Q33870287

Novel arylimidamides for treatment of visceral leishmaniasis

Q33876693

In vitro cultivation and characterization of axenic amastigotes of Leishmania

Q34207763

Life in vacuoles--nutrient acquisition by Leishmania amastigotes.

Q34375990

Sodium antimony gluconate induces generation of reactive oxygen species and nitric oxide via phosphoinositide 3-kinase and mitogen-activated protein kinase activation in Leishmania donovani-infected macrophages

Q34648790

High-throughput screening of amastigotes of Leishmania donovani clinical isolates against drugs using a colorimetric beta-lactamase assay

Q35079712

Novel approach to in vitro drug susceptibility assessment of clinical strains of Leishmania spp

Q36118602

Advances and perspectives in Leishmania cell based drug-screening procedures

Q36641739

The amastigote forms of Leishmania are experts at exploiting host cell processes to establish infection and persist

Q36837840

Leishmania donovani lacking the Golgi GDP-Man transporter LPG2 exhibit attenuated virulence in mammalian hosts

Q37288178

The human leukemia cell line, THP-1: a multifacetted model for the study of monocyte-macrophage differentiation

Q37648485

Visceral leishmaniasis: experimental models for drug discovery

Q37842069

Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it?

Q38188571

Whole-genome comparative RNA expression profiling of axenic and intracellular amastigote forms of Leishmania infantum

Q38354703

Leishmania amastigotes as targets for drug screening.

Q39085580

In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependent

Q39444290

Stage-specific activity of pentavalent antimony against Leishmania donovani axenic amastigotes.

Q39469739

Axenically grown amastigotes of Leishmania infantum used as an in vitro model to investigate the pentavalent antimony mode of action

Q39559595

A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis

Q39614541

An axenic amastigote system for drug screening

Q39783960

Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents

Q39784088

Amphotericin B induces expression of genes encoding chemokines and cell adhesion molecules in the human monocytic cell line THP-1.

Q40856077

Axenic culture of Leishmania amastigotes

Q41082511

An in vitro model for screening antileishmanial drugs: the human leukaemia monocyte cell line, THP-1

Q41611674

In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences

Q41844113

Amphotericin B, identified from a natural product screen, antagonizes CNS inhibitors to promote axon growth via activation of an Akt pathway in neurons

Q43117421

Quantitative proteome profiling informs on phenotypic traits that adapt Leishmania donovani for axenic and intracellular proliferation

Q43584181

Generation of Leishmania donovani axenic amastigotes: their growth and biological characteristics

Q44809758

Colorimetric assay for screening compounds against Leishmania amastigotes grown in macrophages.

Q46488167

Drug cytotoxicity assay for African trypanosomes and Leishmania species

Q46966082

An in vitro system for developmental and genetic studies of Leishmania donovani phosphoglycans.

Q47450122

A simple colorimetric method to screen drug cytotoxicity against Leishmania using the dye Alamar Blue.

Q50506555

Bioluminescent Leishmania expressing luciferase for rapid and high throughput screening of drugs acting on amastigote-harbouring macrophages and for quantitative real-time monitoring of parasitism features in living mice.

Q51547392

Novel Intracellular SbV reducing activity correlates with antimony susceptibility in Leishmania donovani.

Q54027189

Leishmania infantum: Stage-Specific Activity of Pentavalent Antimony Related with the Assay Conditions

Q58852075

Regulation of Leishmania populations within the host. I. the variable course of Leishmania donovani infections in mice

Q67063595

A simple and reproducible method to obtain large numbers of axenic amastigotes of different Leishmania species

Q78359499

Comparison of the expression profiles of promastigotes and axenic amastigotes in Leishmania donovani using serial analysis of gene expression

Q81491725

Expression profiling by whole-genome interspecies microarray hybridization reveals differential gene expression in procyclic promastigotes, lesion-derived amastigotes, and axenic amastigotes in Leishmania mexicana

Q82344940

P433

issue

P407

language of work or name

English

Q1860

P921

main subject

amastigote

Q455445

Leishmania donovani

Q1950752

P304

page(s)

2913-2922

P577

publication date

2013-04-09

P1433

published in

Antimicrobial Agents and Chemotherapy

Q578004

P1476

title

Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay

P478

volume

Reverse relations

cites work (P2860)

Q36933516	A Replicative In Vitro Assay for Drug Discovery against Leishmania donovani
Q49792065	A complex interplay between sphingolipid and sterol metabolism revealed by perturbations to the Leishmania metabolome caused by miltefosine.
Q39003990	Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need
Q30488470	Antileishmanial Activity of Compounds Derived from the Medicines for Malaria Venture Open Access Box Against Intracellular Leishmania major Amastigotes
Q36796525	Antileishmanial and Cytotoxic Activity of Some Highly Oxidized Abietane Diterpenoids from the Bald Cypress, Taxodium distichum
Q28547217	Antiprotozoal Activity Profiling of Approved Drugs: A Starting Point toward Drug Repositioning
Q58850065	Antitrypanosomal 8-Hydroxy-Naphthyridines Are Chelators of Divalent Transition Metals
Q53693383	Autophagic-related cell death of Trypanosoma brucei induced by bacteriocin AS-48.
Q64074570	Biological evaluation and structure activity relationship of 9-methyl-1-phenyl-9H-pyrido[3,4-b]indole derivatives as anti-leishmanial agents
Q57190987	Challenges in drug discovery targeting TriTryp diseases with an emphasis on leishmaniasis
Q47132474	Chemical Validation of Methionyl-tRNA Synthetase as a Druggable Target in Leishmania donovani
Q28079870	Contribution of high-content imaging technologies to the development of anti-infective drugs
Q56565594	Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis
Q28548536	Development and Validation of a Novel Leishmania donovani Screening Cascade for High-Throughput Screening Using a Novel Axenic Assay with High Predictivity of Leishmanicidal Intracellular Activity.
Q35297570	Development and validation of a high-throughput anti-Wolbachia whole-cell screen: a route to macrofilaricidal drugs against onchocerciasis and lymphatic filariasis.
Q89997831	Development of NanoLuc-PEST expressing Leishmania mexicana as a new drug discovery tool for axenic- and intramacrophage-based assays
Q89998156	Development of Trypanosoma cruzi in vitro assays to identify compounds suitable for progression in Chagas' disease drug discovery
Q41933768	Development of a semi-automated image-based high-throughput drug screening system
Q58803746	Development of an automated image analysis protocol for quantification of intracellular forms of Leishmania spp
Q61444423	Discovery of novel hit compounds with broad activity against visceral and cutaneous Leishmania species by comparative phenotypic screening
Q48330948	Discovery of novel, orally bioavailable, antileishmanial compounds using phenotypic screening.
Q99404591	HPLC-Based Activity Profiling for Antiprotozoal Compounds in Croton gratissimus and Cuscuta hyalina
Q28551698	High Throughput Screening Identifies Novel Lead Compounds with Activity against Larval, Juvenile and Adult Schistosoma mansoni
Q60031608	High Throughput and Computational Repurposing for Neglected Diseases
Q28542489	High throughput screening for anti-Trypanosoma cruzi drug discovery
Q35353325	High-throughput screening platform for natural product-based drug discovery against 3 neglected tropical diseases: human African trypanosomiasis, leishmaniasis, and Chagas disease.
Q38599011	Hit and lead criteria in drug discovery for infectious diseases of the developing world
Q28538852	INsPECT, an open-source and versatile software for automated quantification of (Leishmania) intracellular parasites
Q90661828	Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis
Q28551393	Identification of Trypanocidal Activity for Known Clinical Compounds Using a New Trypanosoma cruzi Hit-Discovery Screening Cascade.
Q52676386	Identifying inhibitors of the Leishmania inositol phosphorylceramide synthase with antiprotozoal activity using a yeast-based assay and ultra-high throughput screening platform.
Q57929890	Importance of secondary screening with clinical isolates for anti-leishmania drug discovery
Q28545229	Infrared fluorescent imaging as a potent tool for in vitro, ex vivo and in vivo models of visceral leishmaniasis
Q55459515	Innovation in neglected tropical disease drug discovery and development.
Q41990715	Leishmania and other intracellular pathogens: selectivity, drug distribution and PK-PD.
Q46267456	Marine Algae as Source of Novel Antileishmanial Drugs: A Review
Q30417002	New compound sets identified from high throughput phenotypic screening against three kinetoplastid parasites: an open resource.
Q64996615	Novel chemical starting points for drug discovery in leishmaniasis and Chagas disease.
Q38163392	Overcoming the challenges of drug discovery for neglected tropical diseases: the A·WOL experience
Q58077497	Pharmacological validation of N-myristoyltransferase as a drug target in Leishmania donovani
Q28074697	Plasticity of the Leishmania genome leading to gene copy number variations and drug resistance
Q64068249	Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition
Q27011766	Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis
Q91999810	Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis
Q34975777	Screening strategies to identify new chemical diversity for drug development to treat kinetoplastid infections
Q38695331	Screening the Medicines for Malaria Venture Pathogen Box across Multiple Pathogens Reclassifies Starting Points for Open-Source Drug Discovery.
Q39144812	Snapshot Profiling of the Antileishmanial Potency of Lead Compounds and Drug Candidates against Intracellular Leishmania donovani Amastigotes, with a Focus on Human-Derived Host Cells
Q58898624	Synthesis of carboxyimidamide-substituted benzo[c][1,2,5]oxadiazoles and their analogs, and evaluation of biological activity against Leishmania donovani
Q54214867	Systematic search for benzimidazole compounds and derivatives with antileishmanial effects.
Q92847998	The Qi Site of Cytochrome b is a Promiscuous Drug Target in Trypanosoma cruzi and Leishmania donovani
Q38772165	The development of high-content screening (HCS) technology and its importance to drug discovery
Q64997649	The proteasome as a target: How not tidying up can have toxic consequences for parasitic protozoa.
Q53080458	Topical Treatment for Cutaneous Leishmaniasis: Dermato-Pharmacokinetic Lead Optimization of Benzoxaboroles.
Q36380098	Unravelling the rate of action of hits in the Leishmania donovani box using standard drugs amphotericin B and miltefosine
Q104619435	Unveiling six potent and highly selective antileishmanial agents via the open source compound collection 'Pathogen Box' against antimony-sensitive and -resistant Leishmania braziliensis
Q61818331	Utilization of proliferable extracellular amastigotes for transient gene expression, drug sensitivity assay, and CRISPR/Cas9-mediated gene knockout in Trypanosoma cruzi